The clinical utilization of SNIP1 and its pathophysiological mechanisms in disease

Yinzhong Chen; Wei Guo; Xiucheng Guo; Qiao Wanqing; Zongsheng Yin

doi:10.1016/j.heliyon.2024.e24601

The clinical utilization of SNIP1 and its pathophysiological mechanisms in disease

Heliyon. 2024 Jan 17;10(2):e24601. doi: 10.1016/j.heliyon.2024.e24601. eCollection 2024 Jan 30.

Authors

Yinzhong Chen^{1

2}, Wei Guo³, Xiucheng Guo², Qiao Wanqing², Zongsheng Yin¹

Affiliations

¹ Department of Orthopedics, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
² Department of Orthopedics, the Second Affiliated Hospital of Shandong First Medical University, Tai'an, Shandong, China.
³ Department of Medical Imaging, the Second Affiliated Hospital of Shandong First Medical University, Tai'an, Shandong, China.

Abstract

Smad intranuclear binding protein 1 (SNIP1), a highly conserved nuclear protein, functions as a transcriptional regulator and exerts a significant influence on disease progression. In addition, the N-terminal domain of SNIP1 facilitates its interaction with Smad4, a signaling protein associated with the TGF-β family, and RelA/p65, a transcription factor connected to NF-κB. This interaction further enhances the transcriptional activation of c-Myc-dependent genes. Presently, the primary emphasis in research is directed towards targeting the catalytic domain of SNIP1, as it holds promise as a potential therapeutic target for various diseases. While the significance of SNIP1 in pathological mechanisms remains uncertain, this review aims to comprehensively examine the existing literature on the association between SNIP1 and proteins implicated in the regulation of diverse clinical conditions, including cancer, inflammation, and related diseases.

Keywords: C-Myc; NF-κB pathway; SNIP1; TGF-β pathway.

Publication types

Review